« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 117, Issue 3
, Pages
557-562
, March 2006
The September epidemic of asthma hospitalization: School children as disease vectors
-
A, The annual cycle of asthma hospitalization by age group in Canada by week of the year. Data for all hospitalizations in Canada (excluding Québec) from April 1990 to March 2003 summarized over a sin
A, The annual cycle of asthma hospitalization by age group in Canada by week of the year. Data for all hospitalizations in Canada (excluding Québec) from April 1990 to March 2003 summarized over a single year. B, The annual cycle of hospitalization for respiratory tract infections by age group in Canada by week of the year. Data for all hospitalizations in Canada (excluding Québec) from April 1995 to March 2003 summarized over a single year.
-
A, The cycle of asthma hospitalization of children age 5 to 15 years from April 1990 to March 2003 as multiples of the weekly mean number of hospitalizations over the whole period. B, The cycle of astA, The cycle of asthma hospitalization of children age 5 to 15 years from April 1990 to March 2003 as multiples of the weekly mean number of hospitalizations over the whole period. B, The cycle of asthma hospitalization of children age 5 to 15 years from April 1990 to March 2003 as multiples of the weekly mean number of hospitalizations within each year.
-
Calculated timing by week of the year in weeks from January 1 (left y axis, black line) and magnitude in multiples of the weekly mean (right y axis, white line) of the September epidemic peak by yearCalculated timing by week of the year in weeks from January 1 (left y axis, black line) and magnitude in multiples of the weekly mean (right y axis, white line) of the September epidemic peak by year of age using data aggregated across all study years.
Disclosure of potential conflict of interest: M. Sears has received grants from Merck Frosst Canada and AstraZeneca and is on the speakers bureau for Merck Frosst Canada, AstraZeneca, and Altana Pharma. The rest of the authors have no conflict of interest to disclose.Supported in part by the Firestone Institute for Respiratory Health and by British Lung Foundation/Severin Wunderman Family Foundation Lung Research Programme grant number P00/2.
PII: S0091-6749(05)02592-3
doi: 10.1016/j.jaci.2005.11.034
© 2006 American Academy of Allergy, Asthma and Immunology. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 117, Issue 3
, Pages
557-562
, March 2006
